Back to Search
Start Over
Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
- Source :
- Acta Dermato-Venereologica; 2023, Vol. 103, p1-7, 7p
- Publication Year :
- 2023
-
Abstract
- The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patientreported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well. [ABSTRACT FROM AUTHOR]
- Subjects :
- ATOPIC dermatitis
MEDICAL registries
SKIN diseases
BARICITINIB
QUALITY of life
Subjects
Details
- Language :
- English
- ISSN :
- 00015555
- Volume :
- 103
- Database :
- Complementary Index
- Journal :
- Acta Dermato-Venereologica
- Publication Type :
- Academic Journal
- Accession number :
- 174550345
- Full Text :
- https://doi.org/10.2340/actadv.v103.14153